RETICEP
LIVE

Serial Number

79349364

Owner

Kyoto Drug Discovery & Development Co., Ltd.

Filing Date

Jul 27, 2022

Add to watchlist:

No watchlists yet
View on USPTO

RETICEP Trademark

Serial Number: 79349364 • Registration: 7362054

RETICEP is a trademark filed by Kyoto Drug Discovery & Development Co., Ltd. on July 27, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Kyoto Drug Discovery & Development Co., Ltd. (3 trademarks)

#302, Saito Bio Hills Center

Entity Type: 03

Trademark Details

Filing Date

July 27, 2022

Registration Date

April 23, 2024

Published for Opposition

February 6, 2024

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 9, 2024 FINV
FINAL DISPOSITION NOTICE SENT TO IB
Oct 22, 2024 FICS
FINAL DISPOSITION PROCESSED
Oct 22, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 24, 2024 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 23, 2024 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 11, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 21, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 21, 2024 OPNR
NOTIFICATION PROCESSED BY IB
Feb 6, 2024 GPNX
PUBLISHED FOR OPPOSITION
Feb 6, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 17, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 17, 2024 OP2R
NOTICE OF PUBLICATION
Jan 17, 2024 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 2, 2024 CNSA
REFUSAL PROCESSED BY IB
Jul 22, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 22, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jun 22, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 17, 2023 RFCR
SUSPENSION LETTER WRITTEN
May 16, 2023 CNSL
ASSIGNED TO EXAMINER
May 15, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 20, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 16, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Sep 15, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 15, 2022 REPR